Edition:
Deutschland

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

106.85EUR
3 Jul 2020
Change (% chg)

€-0.15 (-0.14%)
Prev Close
€107.00
Open
€107.40
Day's High
€108.35
Day's Low
€106.40
Volume
442,531
Avg. Vol
752,290
52-wk High
€125.95
52-wk Low
€76.22

About

Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Performance Materials. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and... (more)

Buy/Sell

Sell Hold Buy
2.45 Mean rating from 20 analysts

Overall

Beta: 1.01
Market Cap(Mil.): €12,352.97
Shares Outstanding(Mil.): 129.24
Dividend: 1.20
Yield (%): 1.26
Photo

Daily Briefing: Jobs at a time of pandemic

LONDON Is data flow again in danger of being overtaken by the coronavirus? Today's U.S. June payrolls report is important but like most data it's backward looking.

BRIEF-FDA Approves Avelumab For Urothelial Carcinoma Maintenance Treatment

* FDA - APPROVES AVELUMAB FOR UROTHELIAL CARCINOMA MAINTENANCE TREATMENT

Sigma-Aldrich, not Merck gave misleading info in deal review, EU says

BRUSSELS U.S. drugmaker Sigma-Aldrich provided incorrect and misleading information during an antitrust review of its 2015 takeover by Merck KGaA , EU regulators said on Wednesday as they dropped the German company from their investigation.

Sigma-Aldrich, not Merck gave misleading info in deal review, EU says

BRUSSELS, July 1 U.S. drugmaker Sigma-Aldrich provided incorrect and misleading information during an antitrust review of its 2015 takeover by Merck KGaA, EU regulators said on Wednesday as they dropped the German company from their investigation.

BRIEF-Merck Receives Additional EU Statement In Proceedings Concerning Sigma-Aldrich Acquisition

* RECEIVES EU COMMISSION SUPPLEMENTARY STATEMENT OF OBJECTIONS IN THE PROCEEDINGS CONCERNING THE SIGMA-ALDRICH ACQUISITION

Photo

Daily Briefing: A new quarter

LONDON A quick look back at the Q2 market league tables - the world equity index rose 18% for its biggest three-month gain since 2009.

Photo

Daily Briefing: Turning points

LONDON The end of H1, the end of a quarter, the end of a month - all of them pretty extraordinary with plenty of milestones and records, providing investors with lots to chew over as they prepare to see whether the second half of the year can bring a return to some form of ordinary.

Photo

Daily Briefing: Locking down?

Ten million and counting. That's how many people have been infected by the new coronavirus, while half a million have been killed by it, a Reuters tally shows. But lockdowns are the indicator to watch for and California's decision to close some bars is an ominous sign.

MORNING BID-Locking down?

(A look at the day ahead from EMEA deputy markets editor Sujata Rao. The views expressed are her own.) Ten million and counting. That's how many people have been infected by the new coronavirus, while half a million have been killed by it, a Reuters tally shows. But lockdowns are the indicator to watch for and California's decision to close some bars is an ominous sign. Reopening plans have been paused or postponed in Texas, Florida and Arizona and in the UK, the city of Leicester could be locke

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.12%
Rohstoffe +0.08%
Industrie -0.08%
Konjunktur abhängige Waren & Dienstleistungen -0.23%
Konjunktur unabhängige Waren & Dienstleistungen -0.10%
Finanzindustrie -0.03%
Pharma +0.06%
Technologie +0.22%
Telekommunikation -0.11%